Season 2 (2021-2030)

Neuroscience - Phase1 (1)

Modality Indication Targets Stage Company Project No. Detail
1 Development of a novel c.Abl and LRRK2 dual inhibitor for Parkinson’s Disease Treatment
Small Molecules Parkinson's disease c.Abl/LRRK2 Phase 1 1ST Biotherapeutics Inc. RS-2023-00283009
BACK